Understanding Cumulative Life Course Impairment in Psoriasis: Impact On Patient Management

Authors

  • Marni C. Wiseman, MD, FRCPC
  • Ashley O’Toole, MHSc, MD, FRCPC

Abstract

Psoriasis is a chronic inflammatory skin disease that occurs in an estimated 2% of individuals worldwide. Among the subtypes of the disease, plaque psoriasis is the most common, accounting for 90% of cases. The disease is associated with numerous comorbidities and is now widely recognized as an immune-mediated inflammatory disorder. AIDS 

Author Biographies

Marni C. Wiseman, MD, FRCPC

Dr. Marni C. Wiseman began her dermatology practice in Winnipeg, Manitoba in 2001. In addition to her teaching responsibilities as an Associate Professor and Section Head of Dermatology at the Faculty of Medicine at the University of Manitoba, Dr. Wiseman spends most of her days at her private medical practice as the Medical Director of SKiNWISE Dermatology.

Dr. Wiseman’s areas of clinical and research interest include psoriasis, atopic dermatitis, hidradenitis suppuritiva, acne, and aesthetic dermatology. She is a principal investigator at Wiseman Dermatology Research and has participated in hundreds of clinical trials. Dr. Wiseman is a frequent supervisor and mentor for medical students and residents. She has published extensively in areas of inflammatory skin disease, photodermatosis, and cutaneous malignancy.

Dr. Wiseman’s community commitments are extensive and include involvement with the Canadian Dermatology Association Sun Awareness program. She is an editor of the Journal of Cutaneous Medicine and Surgery and was the chair of the Skin Cancer Disease Site Group at CancerCare Manitoba for 15 years. Dr. Wiseman holds regular outreach skin cancer screening clinics in rural locations in Manitoba, has been featured in many news stories, and regularly presents at meetings and congresses nationally and internationally.

Ashley O’Toole, MHSc, MD, FRCPC

Dr. Ashley O’Toole is a dermatologist with the SKiN Centre for Dermatology in Peterborough, Ontario where she also serves as a sub-investigator for multiple clinical trials. She is an adjunctive professor at Queens University and is involved in teaching medical students and residents.

After receiving a Master’s of Health Science in Health and Behavioural Communication at Ryerson University, Dr. O’Toole received her medical degree from McMaster University in Hamilton, Ontario, and completed her residency in dermatology at the University of Ottawa.

Dr. O’Toole is the author or co-author of 15 publications and is involved in multiple clinical trials on atopic dermatitis, psoriasis, alopecia, acne and vitiligo.

References

Rendon A, Schakel K. Psoriasis pathogenesis and treatment. Int J Mol Sci 2019;20:1475.

Griffiths CEM, et al. Dermatol Ther (Heidelb). 2017;7(Suppl 1):31-41.

Canadian Psoriasis Guidelines Committee. Canadian guidelines for the management of plaque psoriasis, June 2009. http://www.dermatology. ca/psoriasisguidelines. Accessed 2020 May 11.

Canadian Psoriasis Guidelines Addendum Committee. 2016 Addendum to the Canadian Guidelines for the Management of Plaque Psoriasis 2009. J Cutan Med Surg. 2016;20(5):375-431.

Takeshita J, et al. Psoriasis and Comorbid Diseases Part I. Epidemiology. J Am Acad Dermatol. 2017;76(3):377-390.

Dreiher J, et al. Psoriasis and chronic obstructive pulmonary disease: a case-control study. Br J Dermatol. 2008;159(4):956-60.

Ger TY, et al. Bidirectional association between psoriasis and obstructive sleep apnea: A systematic review and meta-analysis. Sci Rep. 2020;10(1):5931.

Rech J, et al. Psoriatic arthritis epidemiology, comorbid diseaseprofiles and risk factors: results from a claims database analysis. Rheumatology Advances in Practice. 2020;0:1.

Alinaghi F, et al. Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies. JAAD. 2019;80:25.

Busse K, Liao W. Which psoriasis patients develop psoriatic arthritis? Psoriasis Forum. 2010;16:17.

De Oliveira M, et al. Psoriasis. Classical and emerging comorbidities. An Bras Dermatol. 2015;90:9.

Habashy J. How does psoriasis affect quality of life? Medscape. updated 2020 Nov 20. Accessed 2021 May 7. https://www.medscape.com/ answers/1943419-30274/how-does-psoriasis-affect-quality-of-life.

Pariser D, et al. Psoriasis Patient Interview Study Group. A multicenter, non-interventional study to evaluate patient-reported experiences of living with psoriasis. J Dermatol Treat. 2015;1–8.

Horn EJ, et al. Association of patient-reported psoriasis severity with income and employment. J Am Acad Dermatol. 2007;57:963.

Warren RB, et al. Cumulative life course impairment in psoriasis: patient perception of disease-related impairment throughout the life course. Br J Dermatol. 2011;164 Suppl 1:1.

Kimball AB, et al. Psoriasis: is the impairment to a patient’s life cumulative? JEADV. 2010;24:989.

Pariente B, et al. Development of the Crohn’s Disease digestive damage score, the Lémann score. Inflamm Bowel Dis. 2011;17:1415.

Linder MD, Kimball AB. Dermatological Diseases and Cumulative Life Course Impairment. Curr Probl Dermatol. 2015 Oct;142(4):498–499.

Strober BE. Clinical goals and barriers to effective psoriasis care. Dermatology and Therapy. 2019;9:5.

Armstrong A, et al. Patient perceptions of clear/almost clear skin in moderate-to-severe plaque psoriasis: results of the Clear About Psoriasis worldwide survey. JEADV 2018;32:2200. JEADV. 2018;32:2200.

Griffiths CEM, et al. “Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.” The Lancet. 2015 Aug 8;386(9993):541-51. doi: 10.1016/S0140-6736(15)60125-8.

Strober, Bruce, et al. “Clinical meaningfulness of complete skin clearance in psoriasis.” Journal of the American Academy of Dermatology. 2016;75(1):77-82.

Elewski BE, et al. “Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75–89 response: results from two phase 3 studies of secukinumab.” Journal of dermatological treatment. 2017 Sep;28(6):492-499.

Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392(10148):650–61.

Blauvelt, Andrew, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo-and active comparator– controlled VOYAGE 1 trial. Journal of the american academy of dermatology. 2017;76(3): 405-417.

Lebwohl M, et al. Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial. British Journal of Dermatology. 2010;162(1):137-146.

Blauvelt A, Reich K, Tsai TF, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: results from the CLEAR study. Journal of the American Academy of Dermatology. 2017;76(1):60-69.

Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. The Lancet. 2015;386(9993):541-551.

Lambert J, et al. Dermatology Life Quality Index in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab or Ustekinumab. Dermatology and Therapy. 2021;1-11.

Poulin Y, et al. Health-related quality of life worsens disproportionately to objective signs of psoriasis after withdrawal of adalimumab therapy. Dermatol Ther. 2014;4:33.

Gladman DD, et al. Treating Psoriasis and Psoriatic Arthritis: Position Paper on Applying the Treat-to-target Concept to Canadian Daily Practice. J Rheumatol. 2017;44:519.

Armstrong A, et al. From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis. JAAD 2017;76:290.

Menter A, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. JAAD. 2019;80:1029.

Amatore F, et al. French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults. JEADV. 2019;33:464.

Saeki H, et al. Japanese guidance for use of biologics for psoriasis. J Dermatol. 2020;47:201.

Evolution of psoriasis endpoint use. IQVIA. 2020 July 31. Accessed 2021 May 7. at https://www.iqvia.com/ blogs/2020/07/evolution-of-psoriasis-endpoint-use

Fleming P, et al. Effect of biologics on depressive symptoms in patients with psoriasis: a systematic review. JEADV. 2015;29:1063.

Saurat JH, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008;158:558.

Marsili F, et al. J Dermatol Treat 2020; Effectiveness of cyclosporine A in patients with moderate to severe plaque psoriasis in a real-life clinical setting in Italy: the TRANSITION study. J Dermatolog Treat. 2022 Feb;33(1):401-407.

Paul C, Cather J, Gooderham M, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol. 2015 Dec;173(6):1387-99.

Mahil SK et al. Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis. Br J Dermatol 2020;183:638.

Armstrong AW, et al. “Comparative Efficacy and Relative Ranking of Biologics and Oral Therapies for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis.” Dermatology and therapy. 2021;11(3):885-905.

Mahil SK, et al. Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis. Br J Dermatol. 2020;183:638.

Warren RB, et al. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy–assessor-blinded clinical trial. 2021;184:50.

Reich K, et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet. 2019;394:831.

Blauvelt A, et al. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial. Br J Dermatol. 2020;182:1348.

Blauvelt A, et al. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial. Br J Dermatol. 2020 Jun;182(6):1348-1358. doi: 10.1111/bjd.19509. Online ahead of print.

Puig L, et al. Drug survival of conventional systemic and biologic therapies for moderate-to-severe psoriasis in clinical practice in Spain: prospective results from the SAHARA study. J Dermatol Treat. 2020;31:344.

Korman NJ. Management of psoriasis as a systemic disease: what is the evidence? Br J Dermatol. 2020;182:840.

Reich K, et al. Ustekinumab decreases work limitations, improves work productivity, and reduces work days missed in patients with moderate-to-severe psoriasis: results from PHOENIX 2. J Dermatolog Treat. 2011;22:337.

https://newsroom.heart.org/news/ biologic-therapy-for-psoriasis-may-reduce-heart-disease

Stebut EV, et al. “IL-17A in psoriasis and beyond: cardiovascular and metabolic implications.” Frontiers in immunology. 2019;10:3096.

Youssef AE, et al. “Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study.” Cardiovascular research. 2019;115(4):721-728.

Downloads

Published

2021-06-01

How to Cite

1.
Wiseman MC, O’Toole A. Understanding Cumulative Life Course Impairment in Psoriasis: Impact On Patient Management. Can Dermatol Today [Internet]. 2021 Jun. 1 [cited 2024 Nov. 23];2(s06):2–15. Available from: https://canadiandermatologytoday.com/article/view/2-s06-wiseman-otoole

Issue

Special Supplement, June 2021

Section

Articles